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Abstract 
Objective:  The objective of this study was to assess the effectiveness of a routine multivitamin 
supplementation program for adults living with HIV in Tanzania. 
Design: We conducted a retrospective cohort study of 67,707 adults enrolled in the Dar es 
Salaam HIV care and treatment program during 2004-2012. 
Methods: The Dar es Salaam HIV care and treatment program intended to provide all adult 
patients with multivitamin supplements (vitamins B-complex, C, and E) free of charge; however, 
intermittent stockouts and other implementation issues did not afford universal coverage. We use 
Cox proportional hazard models to assess the time-varying association of multivitamin 
supplementation with mortality and clinical outcomes.   
Results: The study cohort contributed 41,540 and 129,315 person-years of follow-up time to the 
ART-naïve and ART-experienced analyses, respectively. Among 48,207 ART-naïve adults, 
provision of multivitamins reduced the risk of mortality (adjusted hazard ratio (aHR): 0.69; 95% 
CI: 0.59-0.81), incident tuberculosis (TB) (aHR: 0.83; 0.76-0.91), and meeting ART eligibility 
criteria (aHR: 0.78; 95% CI: 0.73-0.83) after adjustment for time-varying confounding. Among 
46,977 ART-experienced patients, multivitamins reduced mortality (HR: 0.86; 95% CI: 0.80-
0.92), incident TB (aHR: 0.78; 95% CI: 0.73-0.84), and immunologic failure (aHR: 0.70; 95% 
CI: 0.67-0.73). The survival benefits associated with provision multivitamins appeared to be 
greatest during the first year of ART and declined over time (p-value <0.001).  
Conclusion: Multivitamin supplementation appears to be a simple, effective, safe, and scalable 
program to improve survival, reduce incidence of TB, and improve treatment outcomes for adult 
HIV patients in Tanzania. 
Keywords:  HIV, Tuberculosis, micronutrient, nutrition, supplement, cohort study, 
implementation science 
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Introduction 
 In 2016, an estimated 19.5 million people accessed antiretroviral therapy (ART), which is 
the first time that more than half of all people living with human immunodeficiency virus (HIV) 
were on treatment [1]. Notwithstanding marked success in increasing ART coverage, HIV-
infected adults in resource-limited settings still experience high rates of mortality and HIV 
progression as compared with people living with HIV in high-income settings [2, 3]. Late 
initiation of ART with low CD4 T-cell counts and comorbidities, concurrent malnutrition, and 
high risk of exposure to life-threatening pathogens are likely contributors to poor HIV treatment 
outcomes in resource-limited settings [3, 4].  As a result, interventions to slow CD4 T-cell 
decline for ART-naïve individuals, improve CD4 T-cell reconstitution after ART initiation, and 
promote strong, well-balanced immune responses may reduce mortality and improve HIV care 
and treatment outcomes.  
 Micronutrient deficiencies are common among HIV-infected adults in sub-Saharan 
Africa and are known to impact immune responses [5, 6].  Randomized trials among ART-naïve 
populations have found that multivitamin supplements reduce mortality, disease progression, 
CD4 T-cell decline, and viral load [7-10]. A recent randomized trial conducted in Botswana 
determined pre-ART multivitamins containing vitamins B, C, E, and selenium approximately 
halved the risk of HIV progression or CD4 T-cell decline below the ART initiation threshold of 
250 cells/µL [11].  Evidence on the effect of multivitamins for adults on ART is much more 
limited. Small placebo-controlled trials of ART-adjunct multivitamins have yielded mixed 
results on CD4 T-cell reconstitution and immunological markers but were underpowered to 
assess mortality and clinical outcomes [12-15].  A randomized dosing trial of ART-adjunct 
multivitamin supplements containing multiple recommended daily allowances (RDAs) of 
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vitamins B-complex, C and E, versus single RDA supplements conducted in Tanzania found no 
difference in HIV progression; however, it is not clear if single RDA multivitamins provided any 
benefit due to the lack of a placebo group [16]. To the best of our knowledge, no studies have 
evaluated the effectiveness of routine pre-ART or ART-adjunct multivitamin supplementation in 
a programmatic setting.  
 During 2004 to 2012, the urban Dar es Salaam, Tanzania HIV care and treatment 
program provided multivitamins containing B-complex, C, and E as standard of care for ART-
naive and ART-experienced adult patients. Nevertheless, not all patients received multivitamins 
due to intermittent stockouts and other implementation issues. In this large observational cohort 
study, we examined the association of multivitamin supplement provision with mortality and 
treatment outcomes for ART-naïve and ART-experienced adult patients. 
  
Methods 
Study Population 
This study was a retrospective cohort of HIV-infected adult (≥ 15 years of age) men and 
non-pregnant women who were enrolled in the Management and Development for Health 
(MDH)-supported HIV care and treatment program in Dar es Salaam, Tanzania from November 
2004 to September 2012. The study cohort was additionally restricted to individuals who 
attended at least two clinic visits to ensure adequate follow-up for ascertainment of health 
outcomes. Patients could contribute to both ART-naive and ART-experienced periods. The 
MDH HIV care and treatment program was established in 2004 as a partnership between 
Muhimbili University of Health and Allied Sciences, Dar es Salaam City Council, and Harvard 
University with financial support from the Center for Disease Control’s Presidents’ Emergency 
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Plan for AIDS Relief (PEPFAR). During the study period, the MDH program provided HIV care 
and treatment at 47 HIV clinic sites in Dar es Salaam. 
 
Patient Enrollment, Follow-up, and Standard of Care 
All HIV-infected adults enrolled in the program received clinical care and treatment 
following Tanzanian national and World Health Organization (WHO) guidelines [17, 18]. ART-
naïve adult patients were scheduled for clinic visits every 3 to 6 months to receive a clinical 
exam and reassess for ART eligibility.  During 2004 to 2012, all adult patients with WHO HIV 
stage IV disease, CD4 cell count less than 200 cells/µL, or WHO HIV stage III disease with a 
CD4 T-cell count less than 350 cells/µL were considered eligible for ART initiation [19]. The 
multivitamin supplementation program ended in 2012 primarily for financial reasons.  The Dar 
es Salaam HIV care and treatment program instituted a Test-and-Treat Strategy in 2016, which 
occurred after the end of the multivitamin program and beyond the range of data included in this 
study. Antiretroviral drugs were provided free of charge by the Tanzanian government and 
standard first-line regimens included two nucleoside reverse-transcriptase inhibitors (NRTIs) 
[lamivudine (3TC) or emtricitabine (FTC), as well as stavudine (d4T) or zidovudine (ZDV) or 
Tenofovir (TDF)], and one non-nucleoside reverse-transcriptase inhibitor (NNRTI) [efavirenz 
(EFV) or nevirapine (NVP)]. Cotrimoxazole prophylaxis was recommended when CD4 T-cell 
counts were less than 200 cells/μL, and treatment protocols for all opportunistic infections 
followed WHO guidelines [17, 18]. 
Adults receiving ART were scheduled for clinic visits at 2 weeks post-initiation and 
monthly thereafter. Physicians and nurses completed standardized patient forms at each visit to 
capture demographic and clinical information. Patients were screened for tuberculosis (TB) 
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based on a TB screener consisting of cough, fever, night sweats, weight loss and hemoptysis. 
Sputum smears and chest radiographs were administered to those suspected to have TB to assist 
with diagnosis. Nurses measured height at the initial clinic visit and weight and middle upper 
arm circumference at subsequent clinic visits. Body mass index (BMI) was calculated as the 
weight in kilograms (kg) divided by the height in meters squared (kg/m2). Laboratory 
assessments of CD4 T-cell count, hemoglobin (Hb), and alanine aminotransferase (ALT) 
concentrations were scheduled to be performed at program enrollment, time of ART initiation 
and every 6 months during follow-up. HIV viral load quantification was not available during the 
study period.  
 
Provision and composition of multivitamin supplements 
 The Dar es Salaam HIV program provided all ART-naïve and ART-experienced adult 
patients multivitamins free of charge as standard of care based on findings from a randomized 
trial of multivitamins conducted among Tanzanian HIV-infected pregnant women in the pre-
ART era and from other multivitamin studies [7-9, 15, 16, 20]. During the study period, 
intermittent stockouts and other implementation issues (e.g., physician decision or error, missing 
pharmacy pickup, patient refusal, etc.) occurred which resulted in less than universal coverage. 
Adult ART-naïve participants received high-dose multivitamin supplements as standard of care 
that contained 2 to 21 times the RDA of B vitamins (20 mg thiamin, 20 mg riboflavin, 25 mg 
vitamin B6, 100 mg niacin, 50 µg vitamin B12, 0.8 mg folic acid), 2 times the RDA for vitamin 
E (30 mg), and 6 times the RDA for vitamin C (500 mg).  Adults on ART received multivitamin 
supplements that contained a single RDA of B vitamins (1.2 mg thiamin, 1.2 mg riboflavin, 1.2 
mg vitamin B6, 15 mg niacin, 2.4 µg vitamin B12, 0.4 mg folic acid), vitamin E (15 mg), and 
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vitamin C (80 mg). Single RDA multivitamins were provided for patients on ART because a 
randomized trial among Tanzanians on ART determined that multiple RDA multivitamins 
increased ALT to levels that suggest liver toxicity [16].  Between 2004 to 2010 the multivitamin 
supplements used in the program were produced by Tishcon Corporation (Salisbury, MD, USA) 
and by Elys Chemical Industries (Nairobi, Kenya) from 2010 to 2012. 
 
Statistical Analysis 
 All analyses were stratified by ART-naïve and ART-experienced follow-up periods due 
to differences in multivitamin dosage and due to the potential for effect modification by 
concurrent use of ART. The status of time-varying multivitamin provision was updated at each 
patient’s visit. The outcomes of interest for ART-naïve and ART-experienced patients included 
incident events of all-cause mortality, anemia (men Hb <13 g/dL; women Hb <12 g/dL), severe 
anemia (Hb <8.5 g/dL for both sexes), wasting (BMI <18.5 kg/m2), TB, WHO stage III or IV 
disease, any increase in WHO stage, and elevated liver enzymes (ALT >40 IU/L and ALT >200 
IU/L). ART eligibility defined by WHO stage and CD4 T-cell criteria was also included as an 
outcome for the ART-naïve period. Among ART-experienced adults, immunologic failure was 
defined as meeting at least one of the following on or after 168 days on ART: a CD4 less than or 
equal to CD4 at the time of ART initiation, CD4 less than half of the maximum value, or CD4 
less than 100 cells/µl [21, 22]. 
 The Andersen-Gill formulation of the Cox proportional hazard model was used to 
evaluate the time-varying effect of multivitamin provision at the prior visit on subsequent 
outcomes of interest [23]. During the ART-naïve period, time was measured as the interval since 
MDH enrollment, and during the ART-experienced period, the interval since ART initiation. For 
both groups, follow-up began at the time of their first multivitamin ascertainment. Patients were 
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censored at the date of death (for non-mortality outcomes), loss to follow-up (last clinic visit), or 
the last clinic visit date of this study (September 30, 2012).  In the ART-naïve analyses, patients 
were also censored at the time of ART initiation. Covariates that were associated with mortality 
at a p-value less than 0.20 in the univariate analysis were included in the adjusted models. The 
covariates considered for confounding adjustment included: age at visit, sex (male, female), 
district (Ilala, Kinondoni, Temeke), facility level (hospital, health center, dispensary), height 
(cm), BMI, MUAC (<20, 20 to <22, 22 to <25, 25 to <27, ≥27 cm), CD4 T-cell count , 
hemoglobin concentration, ALT, tuberculosis (yes, no), WHO HIV stage (I, II, III, IV), and on 
ART at enrollment (yes, no for ART period). The possible nonlinear relationship between 
continuous covariates (age, height, BMI, CD4 T-cell count, hemoglobin concentration, and ALT) 
with study outcomes was examined with restricted cubic splines [24, 25]. In sensitivity analyses, 
we evaluated potential effect modification of the association of multivitamins with outcomes by 
time. We used cross-product terms which multiplied time-varying multivitamin use by time since 
first multivitamin assessment as a continuous variable and compared models with and without 
this term, with a one degree of freedom likelihood ratio test to assess statistical significance of 
effect modification by time. In addition, we assessed potential bias due to dependent censoring 
(i.e., loss to follow-up) using inverse probability of censoring weights [26]. Because no bias was 
evident in the mortality analysis, we did not pursue this sensitivity analysis further for the other 
outcomes. All statistical tests were two-sided at a 0.05 significance level, and conducted using 
SAS 9.3 (Cary, North Carolina, USA). 
 
Ethics 
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The institutional review boards at the Harvard T. H. Chan School of Public Health (20032) and 
the Tanzanian National Institute of Medical Research (NIMR/HQ/R.8a/Vol IX/1668) approved 
the study.  The study conformed to the principles embodied in the Declaration of Helsinki. 
 
 
Results 
The study cohort consisted of 67,707 HIV-infected non-pregnant adult patients who 
attended 1,731,385 clinic visits and were followed for 170,855 person-years between 2004 to 
2012. A total of 48,207 adults contributed to the ART-naïve analysis with 288,934 patient-visits 
(median 3 visits per patient) and 41,540 person-years of follow-up. As for the ART-experienced 
analysis, 46,977 patients contributed data from 1,389,218 patient-visits (median 25 visits per 
patient) with 129,315 person-years of follow-up time. Characteristics of ART-naïve and ART-
experienced patients at their first multivitamin ascertainment (baseline) are presented in Table 1. 
The mean ages at baseline were 36.4 (standard deviation (SD): 9.7) and 37.7 years (SD: 9.6) for 
ART-naïve and ART-experienced patients, respectively. At the first multivitamin ascertainment 
during the ART-experienced period, the mean CD4 T-cell count was 192 cells/µl (SD: 173), and 
79% of patients had WHO stage III or IV disease.  In addition, 77% and 80% of ART-naïve and 
ART-experienced patients were anemic, respectively. 
 
Multivitamin supplementation among ART-naïve patients 
Multivitamins were provided to 86% of patients at the baseline ART-naïve clinic visit. As 
a sign of minimal potential for confounding by indication, adult ART-naïve patients who 
received multivitamins at the baseline visit were similar, on average, to those who did not 
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receive multivitamins in terms of age, sex, BMI, CD4 T-cell count, anemia status, TB co-
infection, and WHO HIV stage (Supplementary Table 1).  
 The unadjusted and time-varying covariate adjusted hazard ratios for the relationship of 
multivitamin provision with mortality and HIV progression among ART-naïve adults are 
presented in Table 2. Multivitamin provision was associated with reduced risk of all-cause 
mortality in univariate (hazard ratio (HR): 0.54; 95% CI: 0.47-0.62) and time-varying adjusted 
(aHR: 0.69; 0.59-0.81) analyses. Provision of multivitamins was also associated with reduced 
risk of reaching ART eligibility criteria and incident anemia, wasting, tuberculosis and WHO 
stage III or IV disease in time-varying adjusted models. Multivitamin provision also reduced the 
risk of incident ALT >40 in time-varying adjusted models. In sensitivity analyses evaluating 
effect modification by time, we found that the protective association of multivitamins with 
incident severe anemia, wasting, WHO Stage III or IV disease, and ALT > 40 IU/L became 
stronger over time (p-values for effect modification by time<0.05) (Supplementary Table 3).    
 
Multivitamin supplementation among ART-experienced patients 
Among HIV-infected adults receiving ART, multivitamins were provided at 59% of the 
baseline clinic visits. ART-experienced patients who received multivitamins at the baseline visit 
were similar, on average, to those who did not receive multivitamins in terms of age, sex, BMI, 
CD4 T-cell count, anemia status and WHO HIV stage suggesting minimal confounding by 
indication (Supplementary Table 2). 
The unadjusted and time-varying adjusted hazard ratios for the relationship of 
multivitamin use with health outcomes among ART-experienced patients are presented in Table 
3.  Multivitamin provision was associated with decreased risk of mortality (HR: 0.86; 95% CI: 
0.80- 0.92) and immunologic failure (HR: 0.70; 0.67- 0.73) in time-varying adjusted models. 
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ART-adjunct multivitamins also reduced the risk of incident anemia, severe anemia, wasting, 
tuberculosis, and ALT >40 IU/L at subsequent clinic visits.  There was no association of 
multivitamin provision with incident WHO HIV stage III or IV disease or increase in WHO HIV 
stage among adults on ART. In sensitivity analyses, the magnitude of the protective association 
of multivitamins with incident anemia, wasting, and immunologic failure became stronger over 
time (p-values for effect modification by time<0.05; Supplementary Table 4).  In contrast, the 
protective association of multivitamins on mortality attenuated over time (p-value for effect 
modification by time<0.05; Supplementary Table 4) and there was some indication of a harmful 
association after 3 years of ART (aHR: 1.22; 95% CI: 1.06- 1.41). The results indicating effect 
modification of the mortality association by time were materially unchanged when we adjusted 
for dependent censoring using inverse probability of censoring weights (results not shown).  
However, after adjusting for dependent censoring, the harmful association after 3 years on ART 
was elevated but no longer statistically significant (aHR: 1.20; 95% CI: 0.98-1.46). 
 
 Discussion 
  In this large implementation evaluation of a multivitamin supplementation program for 
HIV-infected adults enrolled in the Dar es Salaam HIV care and treatment program, we found 
that routine provision of multivitamin supplements containing vitamins B-complex, C, and E 
provided benefits for both ART-naïve and ART-experienced patients. Among ART-naïve 
patients, multivitamin supplements reduced the risks of mortality, reaching ART eligibility 
criteria and incident anemia, TB, and WHO HIV disease stage progression. Similarly, among 
ART-experienced patients, multivitamins reduced the risks of mortality, immunologic failure,  
and incident TB, anemia, and wasting. It is important to note that the mortality benefits for 
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patients on ART appeared to be greatest, and possibly limited to, the first year of antiretroviral 
treatment. Multivitamins were also found to be safe in terms of hepatotoxicity as assessed by 
ALT for both ART-naïve and ART-experienced patients.  
 Our finding that programmatic provision of multivitamins reduces mortality and 
improves care outcomes for ART-naive patients aligns with the findings of multiple randomized 
placebo-controlled trials [7-11]. Most countries and programs in sub-Saharan Africa have shifted 
to a ‘Test-and-Treat’ Strategy for ART initiation, including Tanzania in 2016. Nevertheless, our 
results indicate that the benefits of multivitamin supplementation for ART-naïve determined in 
randomized trials were replicated at scale, which lends support for a potential effect among 
patients on ART. The mechanisms by which vitamins B-complex, C, and E improve outcomes 
for HIV-infected adults are not completely understood, but it is postulated antioxidant, 
immunomodulatory, and viral replication inhibitive properties are primary contributors [6, 11]. 
The B vitamins are important for lymphocyte proliferation, natural killer cell cytotoxicity, and 
cell-mediated immunity [27]; vitamin C supplementation can improve lymphocyte proliferation 
[28]; and vitamin E may inhibit HIV replication [29]. A randomized trial conducted in Botswana 
also indicated that the addition of selenium to multivitamins containing vitamins B, C, E may 
provide even greater CD4 T-cell and HIV progression benefits for ART-naïve patients [11]. 
Selenium is immunostimulatory and has notable antioxidant and antiviral properties which may 
influence HIV replication [30].  As a result, although we found multivitamins containing 
vitamins B, C, and E improved treatment outcomes for ART-naïve adults, the addition of 
selenium as well as other micronutrients and minerals may provide additional benefit.  Studies 
and randomized trials are warranted to determine the optimal composition and dosage of 
multivitamin supplements for HIV-infected adults.  
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 Program provision of multivitamins also improved survival and reduced the incidence of 
anemia, immunologic failure, wasting and TB for HIV-infected adults receiving ART; however, 
the magnitude of benefit appeared to be attenuated as compared to ART-naïve patients. It is 
conceivable that the relative contribution of multivitamins to survival and improved health 
outcomes may be comparatively less in the presence of the strong beneficial effects of ART.  In 
addition, sensitivity analyses examining effect modification by time revealed that the survival 
benefits associated with multivitamins might be limited to the first year of ART. Multivitamins 
may provide greater beneficial effects on inflammation, immune reconstitution inflammatory 
syndrome (IRIS) and HIV-related causes of death which occur more frequently during the initial 
year of ART [31].  Our analysis also indicated a potentially harmful effect on mortality for ART-
experienced patients who were on ART for 3 years or more, while at the same time we found 
that multivitamins decreased the risk of anemia, wasting, and immunologic failure for these 
patients.  We are unable to explain the biological mechanisms leading to these somewhat 
contradicting findings but cannot rule out residual confounding by indication.   Overall, 
programs that provide multivitamins only during the first year of ART when risk of mortality is 
greatest may be more beneficial in terms of survival impact and cost-effectiveness.  Impact 
evaluations of multivitamin program in others settings are warranted. 
In contrast to the consistent evidence base for ART-naïve patients, randomized trials of 
multivitamins for ART-experienced patients have determined mixed results on CD4 T-cell 
reconstitution and other immunological markers [12-16]. A randomized trial conducted among 
40 HIV-infected adults on ART in the US found multivitamin and mineral supplements 
improved CD4 T-cell counts after 3 months as compared with placebo [13]. In contrast, a recent 
trial of 400 HIV-infected Ugandan adults initiating ART found no effect of single RDA 
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supplements containing vitamins B, C, and E on CD4 T-cell counts up to 18 months [12]. 
Nevertheless, these trials had very limited statistical power to detect a moderate effect of 
multivitamins on CD4 T-cell reconstitution. A major strength of our large observational cohort is 
the sample size afford detection of even modest effects on mortality, immunologic failure, and 
other clinical outcomes.  
 A randomized multivitamin dosing trial conducted in Tanzania by members of our team 
raised concern that multiple RDA multivitamins may increase the risk of hepatotoxicity, as 
indicated by elevated ALT, among HIV-infected adults on ART [16]. The mechanism of action 
by which multiple RDA multivitamins might elevate ALT in the presence of ART remains 
unknown. Nevertheless, in this observational cohort study, we found that single dose RDA 
multivitamins for ART-experienced adults and multiple RDA multivitamin appear to be safe in 
terms of hepatotoxicity. As a result, the benefits of these multivitamin doses appear to outweigh 
any potential risks. 
 This study has several limitations. First, due to the observational nature of the study we 
cannot rule out the risk of residual bias due to unmeasured confounding. Nevertheless, we 
attempted to minimize the potential for confounding by using rigorous statistical methods that 
included time-varying exposures and adjustment for numerous possible confounders, including 
allowing for non-linear continuous relationships with the outcomes. Second, our pharmacy 
database only included information on whether or not a patient received a bottle of 
multivitamins, but did not have data on adherence to the supplements. Accordingly, we likely 
underestimated the potential benefits of multivitamin supplements due to suboptimal adherence. 
Implementation studies on adherence counseling can guide strategies to maximize adherence to 
both multivitamins and ART. In addition, the MDH program used WHO HIV disease stage and 
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CD4 T-cell count criteria to determine ART eligibility during the study period. Therefore, our 
findings may not be directly generalizable to programs using a Test and Treat Strategy where 
patients tend to patients initiate ART in a healthier state and at higher CD4 T-cell counts.   
  This implementation evaluation determined program provision of multivitamin 
supplements containing vitamins B-complex, C, and E was associated with improved survival, 
reduced incidence of TB and provided other clinical benefits for both ART-naïve and ART-
experienced adults in Tanzania. A major strength of our study is that it represents real-world 
implementation of multivitamin supplementation program within a large HIV care and treatment 
program. The program was scaled to over 50,000 participants during an 8-year period  from 2004 
to 2012. Randomized controlled trials may overestimate the programmatic impact of 
interventions due to selective recruitment criteria and intensified adherence and retention 
strategies. Overall, our results indicate that multivitamin supplementation appears to be a simple, 
low-cost, effective, safe, and scalable program to improve survival and health outcomes for HIV-
infected receiving care in Tanzania and likely similar settings. Research is needed to determine 
the optimal composition and dosage of multivitamin supplements along with interventions to 
support adherence to both multivitamins and ART to maximize the potentially synergistic health 
benefits at scale. 
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Table 1. Characteristics of 48,207 ART-naïve and 46,977 ART-experienced adult patients1 
enrolled in the HIV treatment and care program in Dar es Salaam, Tanzania from 2004 to 2012 at 
first multivitamin ascertainment (baseline).  
 
Variable 
ART-naïve  
% or  Mean (SD) 
(N = 48,207) 
ART-experienced 
% or Mean (SD) 
(N = 46,977) 
Age, mean years 36.4 (9.7)  37.7 (9.6) 
Male sex 29  30 
Year     
- 2004 to <2006, % 4  9 
- 2006 to <2008, % 24  32 
- 2008 to <2010, % 46  39 
- After 2010, % 27  20 
District of Dar es Salaam    
- Ilala, %  28  39 
- Kinondoni, %  38  33 
- Temeke, %  34  28 
Facility level    
- Hospital, %  85  84 
- Health center, %  6  6 
- Dispensary, %  9  10 
Education     
- Primary, %  66  63 
- Secondary, % 29  31 
- Advanced, % 5  5 
Marital Status     
- Married/cohabitating, % 50  49 
- Single, % 13  13 
- Widowed/divorced/separated, % 37  38 
Body mass index (BMI), kg/m2 21.9 (4.8)  21.6 (4.7) 
Wasting (BMI <18.5 kg/m2), % 24  25 
CD4 T-cell count, cells/µL 281 (249)  192 (173) 
Anemia (males Hb <13 g/dL, female <12 g/dL), 
% 
77  80  
Severe anemia (Hb < 8.5 g/dL), % 18  17  
Alanine aminotransferase (ALT) > 40 IU/L, % 11  13  
Tuberculosis, % 11  12  
WHO HIV stage     
- I, % 
- Single, % 
- Widowed/divorced/separated, % 
 
18  6  
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Variable 
ART-naïve  
% or  Mean (SD) 
(N = 48,207) 
ART-experienced 
% or Mean (SD) 
(N = 46,977) 
- II, % 
- Single, % 
- Widowed/divorced/separated, % 
 
23  15  
- III, % 
- Single, % 
- Widowed/divorced/separated, % 
 
44  54  
- IV, % 
- Single, % 
- Widowed/divorced/separated, % 
 
15  25  
Multivitamin provision, % 86  59  
1Patients can contribute follow-up visits to both ART-naive and ART-experienced periods. 
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Table 2. Association of multivitamin supplement provision with mortality and incident1 health outcomes for HIV-infected ART-naïve 
adult patients in Management and Development for Health, Dar es Salaam, Tanzania from 2004 to 2012 (n=48,207) 
  Unadjusted Time-varying  adjusted5 
Outcome 
Cases  
n (%) 
Hazard Ratio2 
Estimate 
(95% CI) 
p-value 
Hazard Ratio2 
Estimate 
(95% CI) 
p-value 
All-cause mortality 1,427 (3%) 0.54 (0.47- 0.62) <0.001 0.69 (0.59- 0.81) <0.001 
ART eligibility3  8,413 (43%) 0.76 (0.71- 0.80) <0.001 0.78 (0.73- 0.83) <0.001 
Incident anemia4  6,157 (56%) 0.67 (0.62- 0.71) <0.001 0.90 (0.84- 0.97) 0.005 
Incident severe anemia4  4,696 (12%) 0.61 (0.56- 0.65) <0.001 0.92 (0.85- 1.00) 0.05 
Incident wasting (BMI < 18.5 kg/m2) 7,479 (21%) 0.66 (0.62- 0.70) <0.001 0.81 (0.76- 0.86) <0.001 
Incident tuberculosis 4,347 (10%) 0.63 (0.58- 0.68) <0.001 0.83 (0.76- 0.91) <0.001 
Incident WHO Stage III or IV 8,708 (44%) 0.61 (0.58- 0.65) <0.001 0.73 (0.69- 0.78)  <0.001 
Any increase in WHO HIV staging 15,031 (37%) 0.74 (0.71- 0.77) <0.001 0.81 (0.77- 0.85) <0.001 
Incident ALT >40 IU/L 7,995 (19%) 0.71 (0.67- 0.75) <0.001 0.90 (0.84- 0.96) 0.002 
Incident ALT >200 IU/L 314 (<1%) 0.49 (0.37- 0.64) <0.001 0.74 (0.55- 1.01) 0.06 
1 Individuals with event of interest at baseline excluded from the analysis.  
2  Hazard ratio estimates compare patients who received multivitamins to the reference group of patients who did not. 
3 Patients who were eligible for ART within 30 days of program enrollment were excluded from ART eligibility analysis. 
4 Anemia: males Hb <13 g/dL, female <12 g/dL; severe anemia: <8.5 g/dL for both sexes. 
5 Model adjusted for covariates with p-value < 0.20 in the univariate time to mortality models when covariate was not the outcome: age at 
baseline, sex, district, facility level, height, BMI, wasting at visit, MUAC at visit, CD4 cell count at visit, hemoglobin (Hb) at visit, anemia at 
visit, ALT at visit, tuberculosis at visit, WHO HIV stage, and on ART at within 60 days of enrollment. Time-varying analyses used updated 
covariates. Missing indicator method used for missing covariate observations in the adjusted models. 
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Table 3. Association of multivitamin supplement provision with mortality and incident1 health outcomes for HIV-infected ART-
experienced adult patients in Management and Development for Health, Dar es Salaam, Tanzania from 2004 to 2012 (n= 46,977) 
  Unadjusted Time-varying adjusted5 
Outcome 
Cases 
n (%) 
Hazard Ratio2 
Estimate 
(95% CI) 
p-value 
Hazard Ratio2 
Estimate 
(95% CI) 
p-value 
All-cause mortality 4,790 (10%) 0.79 (0.75- 0.84) <0.001 0.86 (0.80- 0.92) <0.001 
Incident anemia3 5,695 (64%) 0.84 (0.80- 0.89) 0.78 0.83 (0.78- 0.88) <0.001 
Severe incident anemia3 4,418 (11%) 0.75 (0.70- 0.79) <0.001 0.88 (0.82- 0.95) 0.001 
Incident BMI < 18.5 kg/m2 7,747 (22%) 0.83 (0.79- 0.87) <0.001 0.83 (0.79- 0.88)  <0.001 
Immunologic failure4 15,577 (36%) 0.71 (0.69- 0.73) <0.001 0.70 (0.67- 0.73) <0.001 
Incident tuberculosis 4,642 (11%) 0.81 (0.76- 0.86) <0.001 0.78 (0.73- 0.84) <0.001 
Incident WHO HIV Stage III or IV 3,709 (37%) 0.85 (0.79- 0.91) <0.001 0.96 (0.88- 1.04) 0.27 
Any increase in WHO HIV stage 5,516 (16%) 0.87 (0.83- 0.92) <0.001 1.02 (0.95- 1.09) 0.62 
Incident ALT >40 IU/L 10,267 (25%) 0.73 (0.70- 0.76) <0.001 0.81 (0.77- 0.85) <0.001 
Incident ALT >200 IU/L 383 (<1%) 0.67 (0.55- 0.82) <0.001  0.82 (0.65- 1.05) 0.12 
 
1 Individuals with event of interest at baseline excluded from the analysis . 
2  Hazard ratio estimates compare patients who received multivitamins to the reference group of patients who did not. 
3 Anemia: males Hb <13 g/dL, female <12 g/dL; severe anemia: <8.5 g/dL for both sexes. 
4 Immunologic failure: On or after 168 days on ART, CD4 count ≤ CD4 at baseline, CD4 < half of the maximum value, or CD4 < 100 cells/µl. 
5 Model adjusted for covariates with p-value < 0.2 in the univariate time to mortality models when covariate was not the outcome: age at baseline, sex, 
district, facility level, height, BMI, wasting at visit, MUAC at visit, CD4 cell count at visit, Hb at visit, anemia at visit, ALT at visit, tuberculosis at visit, 
WHO HIV stage, and on ART within 60 days of enrollment). Time-varying analyses used updated covariates. Missing indicator method used for missing 
covariate observations in the adjusted models. 
